Keeping You Updated
PharmaVentures acts as exclusive advisor to sanofi-aventis in landmark divestment deal with Covance
Oxford, UK. 01 October 2010: PharmaVentures are pleased to announce that they acted as transaction advisors and sale process executioners for sanofi-aventis in their strategic deal with Covance. Under the terms of the agreement, sanofi-aventis will retain access to some of the capabilities which have been divested to Covance as part of a long-term strategic alliance. Covance will provide sanofi-aventis with a 10-year sole source relationship for central lab services.
PharmaVentures has built considerable experience in the M&A field including divestments of manufacturing and R&D businesses. Fintan Walton, CEO, PharmaVentures Ltd said: “The pharmaceutical industry is undergoing a significant transformation with more complex deal structures. The engagement with sanofi-aventis capitalized on PharmaVentures vast experience in complex strategic partnerships and deal transactions”.
Over the past 19 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies.
For press enquiries, please contact:
Dr Fintan Walton, CEO
PharmaVentures
+44 (0) 1865 332700
- ends -
Note to Editors
PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. Its subsidiary PharmaTelevision produces the highly popular PharmaDeals® range of intelligence products including analysis tools and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).
Now in its 18th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.